Number of the records: 1  

Synthesis of LacdiNAc-terminated glycoconjugates by mutant galactosyltransferase – A way to new glycodrugs and materials

  1. 1.
    SYSNO ASEP0327139
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleSynthesis of LacdiNAc-terminated glycoconjugates by mutant galactosyltransferase – A way to new glycodrugs and materials
    Author(s) Bojarová, Pavla (MBU-M) ORCID
    Křenek, Karel (MBU-M)
    Wetjen, K. (DE)
    Adamiak, K. (DE)
    Pelantová, Helena (MBU-M) ORCID, RID
    Bezouška, Karel (MBU-M)
    Elling, L. (DE)
    Křen, Vladimír (MBU-M) RID, ORCID
    Source TitleGlycobiology. - : Oxford University Press - ISSN 0959-6658
    Roč. 19, č. 5 (2009), s. 509-517
    Number of pages9 s.
    Languageeng - English
    CountryUS - United States
    Keywordsenzymatic synthesis ; glycomimetics ; glycosyltransferase
    Subject RIVCE - Biochemistry
    R&D ProjectsGP203/09/P024 GA ČR - Czech Science Foundation (CSF)
    GA204/06/0771 GA ČR - Czech Science Foundation (CSF)
    OC 136 GA MŠMT - Ministry of Education, Youth and Sports (MEYS)
    LC06010 GA MŠMT - Ministry of Education, Youth and Sports (MEYS)
    CEZAV0Z50200510 - MBU-M (2005-2011)
    UT WOS000265096000007
    DOI10.1093/glycob/cwp010
    AnnotationHuman placental b1,4-galactosyltransferase-I (EC 2.4.1.38) transfers the galactosyl moiety from UDP-Gal to various GlcNAc or Glc acceptors in vivo. Here, we describe the construction of its Y284L mutant as a His6propeptidecatb4GalT1 construct, in which the Gal-transferase aktivity was totally abolished in favor of its GalNAc-transferase activity. We used this mutant in the synthesis of three monoand bivalent LacdiNAc glycomimetics with good yields. These compounds proved to be powerful ligands of two activation receptors of natural killer cells, NKR-P1 and CD69.A synthetic bivalent tethered di-LacdiNAc is the best currently known precipitation agent for both of these receptors and has promising potential for the development of immunoactive glycodrugs
    WorkplaceInstitute of Microbiology
    ContactEliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231
    Year of Publishing2010
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.